In addition, somatic mutations in cancer cells, including loss-of-function mutations in JAK1/2, APLNR, PTPN2, and PBRM1, significantly correlate with the efficacy of cancer immunotherapies [102,103,104,105,106,107,108]. This evidence concerns the gene PTPN2 and cancer.